Literature DB >> 3802022

Retrospective and prospective tumor staging evaluating prognostic factors in operated bronchus carcinoma patients.

K Kayser, H Bülzebruck, G Probst, I Vogt-Moykopf.   

Abstract

Survival, pTN stages, and cell type of patients operated on for bronchus carcinoma were evaluated in a retrospective study and compared with data obtained in a prospective study. One thousand three hundred thirty-two patients with potential curative resected lung carcinoma were included in the retrospective study. Two hundred eighty-two patients with potential curative resected lung carcinoma were analyzed in the prospective study. Data showed similarities in distribution of cell type and relative frequency of pT1 stage in both collectives. Major differences between both studies were obtained in relative frequencies of pT3, and pN0, pN1, and pN2 stages. Survival of patients grouped according to cell type revealed differences between patients suffering from epidermoid-adeno carcinoma and patients suffering from small anaplastic carcinoma--large cell anaplastic carcinoma in both studies. Patients stated as pN0 stages showed more favourable prognosis in the prospective study compared with patients of the retrospective study. Two-year survival rates of patients grouped into a pT1pN0 stage and into a pT2pN0 stage had similar survival rates in both studies. Survival of these cohorts compared with patients staged as pT1pN1 and pT2pN1 was statistically significantly better. The data indicate that patients suffering from pT1pN1 or pT2pN1 tumors should be classified as Stage II tumors.

Entities:  

Mesh:

Year:  1987        PMID: 3802022     DOI: 10.1002/1097-0142(19870115)59:2<355::aid-cncr2820590232>3.0.co;2-e

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  2 in total

1.  Cyclin D1 overexpression is an indicator of poor prognosis in resectable non-small cell lung cancer.

Authors:  J S Keum; G Kong; S C Yang; D H Shin; S S Park; J H Lee; J D Lee
Journal:  Br J Cancer       Date:  1999-09       Impact factor: 7.640

Review 2.  Concurrent administration of Docetaxel and Stealth liposomal doxorubicin with radiotherapy in non-small cell lung cancer : excellent tolerance using subcutaneous amifostine for cytoprotection.

Authors:  M I Koukourakis; K Romanidis; M Froudarakis; G Kyrgias; G V Koukourakis; G Retalis; N Bahlitzanakis
Journal:  Br J Cancer       Date:  2002-08-12       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.